Tazemetostat
Withdrawn or never marketedMeasured in people, not heightBy mouthSmall moleculeAlso Tazverik
A cancer drug that blocked one of the enzymes whose loss makes children grow unusually large.
An EZH2 inhibitor. It held accelerated FDA approval from 2020 for EZH2-mutant relapsed or refractory follicular lymphoma, and for metastatic or locally advanced epithelioid sarcoma from age 16. It was the only drug against any of the three overgrowth-syndrome methyltransferases.
Risks. It was pulled from every market in March 2026 because patients taking it developed blood cancers.
On this page
- At the growth plate, members only
- Risks and side effects, members only
The rest of this page is for members
What has been measured, in whom, with every source, and what it does to the rest of you. And every article in the library.
Join for $11.99Lifetime · 3 of 10 founding spots left
Tax is added at checkout (VAT/GST where it applies).
Renews every month at the current price plus tax until you cancel. Cancel from your account before the next monthly charge to stop it.
Card purchases are sold and charged by Link (Stripe) under Link's terms and refund policy.
Already a member? Sign in
Educational content, not medical advice. Nothing here is a recommendation to take or stop taking anything — talk to a doctor about your own situation.